Vor Biopharma (NASDAQ:VOR) Stock Price Down 5.8% Following Insider Selling

Vor Biopharma Inc. (NASDAQ:VOR) shares fell 5.8% on Monday following insider selling activity. The stock traded as low as $17.11 and last traded at $17.0040. 211,115 shares traded hands during mid-day trading, a decline of 78% from the average session volume of 965,964 shares. The stock had previously closed at $18.05.

Specifically, Director Ra Capital Management, L.P. sold 589,257 shares of the business’s stock in a transaction on Monday, April 6th. The shares were sold at an average price of $16.59, for a total value of $9,775,773.63. Following the completion of the transaction, the director owned 4,555,741 shares of the company’s stock, valued at $75,579,743.19. The trade was a 11.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Ra Capital Management, L.P. sold 260,000 shares of the company’s stock in a transaction on Thursday, April 2nd. The stock was sold at an average price of $18.23, for a total transaction of $4,739,800.00. Following the completion of the transaction, the director directly owned 5,144,998 shares of the company’s stock, valued at approximately $93,793,313.54. The trade was a 4.81% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure.

Analyst Ratings Changes

A number of brokerages recently weighed in on VOR. Weiss Ratings reissued a “sell (d-)” rating on shares of Vor Biopharma in a research report on Wednesday, January 21st. TD Cowen began coverage on shares of Vor Biopharma in a research report on Wednesday, December 17th. They set a “buy” rating on the stock. Jefferies Financial Group began coverage on shares of Vor Biopharma in a research report on Monday, March 30th. They set a “buy” rating and a $50.00 price target on the stock. JPMorgan Chase & Co. cut their price target on shares of Vor Biopharma from $43.00 to $40.00 and set an “overweight” rating on the stock in a research report on Friday, December 19th. Finally, Wall Street Zen raised shares of Vor Biopharma from a “strong sell” rating to a “hold” rating in a research report on Saturday. Two research analysts have rated the stock with a Strong Buy rating, six have assigned a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $50.67.

Vor Biopharma Stock Up 3.6%

The company’s fifty day moving average price is $14.29 and its 200 day moving average price is $17.27. The company has a market capitalization of $823.09 million, a P/E ratio of -0.04 and a beta of 1.92.

Institutional Trading of Vor Biopharma

Several large investors have recently made changes to their positions in the company. RA Capital Management L.P. boosted its position in shares of Vor Biopharma by 172.7% during the 4th quarter. RA Capital Management L.P. now owns 5,404,998 shares of the company’s stock worth $70,697,000 after acquiring an additional 3,422,697 shares in the last quarter. Fcpm Iii Services B.V. boosted its position in shares of Vor Biopharma by 852.8% during the 4th quarter. Fcpm Iii Services B.V. now owns 3,617,354 shares of the company’s stock worth $47,315,000 after acquiring an additional 3,237,714 shares in the last quarter. Frazier Life Sciences Management L.P. acquired a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $33,275,000. Paradigm Biocapital Advisors LP acquired a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $22,890,000. Finally, NEXTBio Capital Management LP acquired a new stake in shares of Vor Biopharma during the 4th quarter worth approximately $13,080,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma, Inc is a clinical-stage biotechnology company focused on the development of next-generation, allogeneic cell therapies for patients with hematologic malignancies. The company’s proprietary platform leverages genome editing to engineer donor-derived hematopoietic stem cells (HSCs), enabling the generation of off-the-shelf therapeutic candidates designed to overcome limitations of traditional autologous and matched donor transplants. By targeting key surface antigens and reconstituting the patient’s immune system, Vor aims to deliver curative potential with reduced treatment timelines and broader patient applicability.

The lead program, VOR33, is a CD33-edited HSC product candidate being evaluated in relapsed or refractory acute myeloid leukemia (AML) and high-risk myelodysplastic syndromes (MDS).